Compare FNB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | LEGN |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | FNB | LEGN |
|---|---|---|
| Price | $17.46 | $22.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $18.64 | ★ $69.33 |
| AVG Volume (30 Days) | ★ 4.4M | 2.1M |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 28.48 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $1,587,400,000.00 | $909,045,000.00 |
| Revenue This Year | $17.82 | $68.52 |
| Revenue Next Year | $8.12 | $48.63 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | 6.34 | ★ 74.75 |
| 52 Week Low | $10.88 | $20.21 |
| 52 Week High | $17.93 | $45.30 |
| Indicator | FNB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 43.37 |
| Support Level | $16.86 | $20.21 |
| Resistance Level | $17.90 | $24.12 |
| Average True Range (ATR) | 0.33 | 1.04 |
| MACD | -0.07 | 0.37 |
| Stochastic Oscillator | 57.21 | 52.43 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.